)
Heartbeam (BEAT) investor relations material
Heartbeam Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Advanced heart attack detection initiatives with clinical validation ahead of schedule, including completed enrollment in ALIGN-ACS and over 50% enrollment in HEADSTART-ACS pilot studies; FDA pre-submission completed and new product form factors developed.
Initial commercial launch underway, targeting concierge practices and integrated network partnerships, with multiple agreements signed in four U.S. regions and positive feedback from physicians and patients.
Proprietary TriCor 3D signal reconstruction technology embedded in multiple form factors, protected by 25+ issued patents worldwide, with recent additions expanding acoustic sensing and fluid monitoring capabilities.
Strategic shift to licensing technology and expanding into international markets, notably Indonesia, with pilot studies and partnerships supporting future growth.
Leadership changes implemented, with the founder assuming principal executive officer duties following CEO and board member departures.
Financial highlights
Net cash used in operating activities was $3.3 million for Q2 2026, a 7% decrease from Q1 2026 and a 3% decrease year-over-year.
Net loss for Q2 2026 was $5.0 million, or $(0.10) per share, including one-time items; adjusted net loss was $4.1 million, down 12% sequentially and 17% year-over-year.
Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026, following an $11.5 million capital raise in April.
Operating expenses for Q2 2026 were $5.1 million, with SG&A at $2.8 million and R&D at $2.3 million.
No revenue generated for the three and six months ended June 30, 2026.
Outlook and guidance
Cash runway extended into 2027 due to reduced cost profile and capital raise, supporting continued execution of strategic priorities.
Operating cash outflows expected to trend below $14 million for full year 2026, with Q4 baseline spend projected under $2.5 million per quarter.
Management expects no material commercial revenue in 2026 and ongoing operations depend on raising additional capital.
Pivotal heart attack detection trial anticipated to begin before year-end, pending FDA feedback.
Break-even point estimated at fewer than 30,000 patients, with current contracts covering thousands and significant growth potential in major U.S. geographies.
- Directors and auditor approved; equity plan amendment failed; updates set for August.BEAT
AGM 2026 - Two board nominees, including the CEO, have withdrawn from re-election with no replacements named.BEAT
Proxy filing - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - FDA-cleared at-home 12-lead ECG platform targets $40B market with scalable, AI-driven growth.BEAT
Investor presentation - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - Net loss narrowed, cash burn fell, and $11.5M funding supports clinical and commercial growth.BEAT
Q1 2026 - FDA-cleared 12-lead ECG platform targets $40B market with at-home cardiac monitoring innovation.BEAT
Investor presentation - FDA-cleared ECG tech launches with strong demand, narrowing losses, and AI-driven growth ahead.BEAT
Q4 2025 - AIMIGo nears FDA clearance as Q2 loss hits $5M, cash burn raises going concern risk.BEAT
Q2 2024
Next Heartbeam earnings date
Next Heartbeam earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)